“With the addition of BioPharm Systems, Perficient has strengthened our consulting offerings to healthcare and life sciences ,” said Jeffrey Davis, Perficient’s chief executive officer and president. "Furthermore, BioPharm Systems brings impressive bill rates and margins, important intellectual property assets and a proven track record.”
The acquisition of BioPharm Systems:
- Strengthens Perficient’s overall Oracle partnership and capabilities by bringing extensive experience in the implementation, integration, migration, and hosting of Oracle's Health Sciences applications;
- Adds more than 50 consulting, technology, sales and support professionals; and
- Adds client relationships with leading life sciences enterprise customers including Bayer, CR Bard, Halozyme Therapeutics, Ikaria, Johnson & Johnson, Medtronic, Pfizer, St. Jude Medical, Stryker, and Sunovion, among others.
BioPharm Systems President Alex Sefanov will stay on with the firm.
The closing consideration paid in the transaction is approximately $17.6 million and includes approximately $11.4 million in cash and approximately $6.2 million worth of Perficient common stock. BioPharm System's $15 million annual revenues will be added to Perficient’s annualized revenues which are now approaching $450 million, and the transaction is expected to be accretive.